Immunotherapy of childhood cancer: from biologic understanding to clinical application

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room #1-3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892-1104, USA.
Current opinion in pediatrics (Impact Factor: 2.74). 11/2009; 22(1):2-11. DOI: 10.1097/MOP.0b013e3283350d3e
Source: PubMed

ABSTRACT Most children with cancer can be cured with combination regimens of chemotherapy, radiation, surgery, or all. However, standard therapies are toxic to normal tissues, cancer cells commonly develop resistance to chemotherapy, and relapsed malignancy is a leading cause of mortality in pediatrics. Elucidation of the principles of the normal immune response and tumor biology, coupled with technological developments, have led to important advances in the field of cancer immunotherapy. This review summarizes the biologic basis of cancer immunotherapy and highlights recent examples of progress in the application of novel humoral and cellular immunotherapies to children and adolescents with malignancy.
Clinical trials of immunotherapy for pediatric cancer have recently been initiated. To date, most immune-based therapies have been well tolerated and some have shown clinically significant activity against specific refractory high-risk malignancies.
Recent clinical trial results provide proof-of-principle that cancer immunotherapy has the capacity to overcome chemotherapy resistance without the usual toxicities associated with cytotoxic regimens. Immunotherapy holds promise in the treatment of children and adolescents with cancer and has the potential to improve both survival and quality of life.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the survival of pediatric patients affected by hematological malignancies being improved in the last 20 years by chemotherapy and hematopoietic stem cell transplantation, a significant amount of patients still relapses. Treatment intensification is limited by toxic side effects and is constrained by the plateau of efficacy, while the pipeline of new chemotherapeutic drugs is running short. Therefore, novel therapeutic strategies are essential and researchers around the world are testing in clinical trials immune and gene-therapy approaches as second-line treatments. The aim of this review is to give a glance at these novel promising strategies of advanced medicine in the field of pediatric leukemias. Results from clinical protocols using new targeted "smart" drugs, immunotherapy, and gene therapy are summarized, and important considerations regarding the combination of these novel approaches with standard treatments to promote safe and long-term cure are discussed.
    Frontiers in Oncology 04/2013; 3:106. DOI:10.3389/fonc.2013.00106
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several strategies have been proven to improve transfection efficiency of polyethylenimine (PEI) as non viral gene delivery vector. In this study a nucleic acid aptamer specific for protein tyrosine kinase 7 (PTK7) surface marker, sgc-8c, was conjugated electrostatically to pre-formed 10 kDa PEI/plasmid DNA polyplexes, and the ability of the conjugate to transfer genetic materials was evaluated in MOLT-4 human acute lymphoblastic leukemia T-cells, which express PTK7 on their surfaces. Polyplexes (plasmid DNA-vector conjugates), prepared using PEI-sgc-8c conjugate and pCMVLuc as reporter gene, were characterized in terms of particle size, surface charge and the extent of DNA condensation. Polyplexes were also evaluated for cytotoxicity using the MTS colorimetric assay, and for transfection efficiency in MOLT-4 cells and compared to results in U266 cells, which lack cell surface PTK7. Relative to pDNA/PEI, the size of pDNA/PEI/sgc-8c aptamer polyplexes increased with decreasing zeta potential. In MOLT-4 cells, pDNA/PEI/sgc-8c aptamer polyplexes exhibited a 6 to almost 8 fold increase in transfection efficiency compared to that of pDNA/PEI polyplex, indicating that conjugation of sgc-8c aptamer to pre-formed 10 kDa PEI/plasmid DNA polyplexes achieved effective targeting without covalent attachment, while receptor-mediated conducted transfection was confirmed by performing competitive transfection experiment and cellular uptake study. The results of this study provide an example of the usefulness of a nucleic acid aptamer in the form of non-covalent, electrostatic conjugates as an approach to enhance transfection efficiency of a polycation vector such as PEI without significant induced cytotoxicity. This article is protected by copyright. All rights reserved.
    The Journal of Gene Medicine 06/2013; 15(6-7). DOI:10.1002/jgm.2718 · 1.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
    Frontiers in Oncology 12/2012; 2:195. DOI:10.3389/fonc.2012.00195


Available from